Curis to Present at 7th Annual BIO Investor Forum Conference

* Reuters is not responsible for the content in this press release.

Thu Oct 23, 2008 7:30am EDT 

CAMBRIDGE, Mass.--(Business Wire)--
Curis, Inc. (NASDAQ: CRIS), a drug development company focused on
developing the next generation of proprietary targeted medicines for
cancer treatment, today announced that the Company will be presenting
at the 7th Annual BIO Investor Forum Conference, at 3:45 p.m. local
time (6:45 p.m. EDT) on October 30, 2008, at the Palace Hotel in San
Francisco, California.

   Daniel R. Passeri, Curis' President and Chief Executive Officer,
will provide an overview of the status of GDC-0449, an
orally-administered small molecule inhibitor of the Hedgehog pathway
that is currently in Phase II clinical testing under collaboration
with Genentech. Mr. Passeri also will discuss CUDC-101, CUDC-305 and
Curis' other targeted cancer programs, in addition to other corporate
activities.

   There will also be a corresponding webcast of the presentation,
which can be accessed by visiting:

   http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=
CRIS&item_id=1995924

   (Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)

   The presentation will be archived shortly after the live event and
available for 30 days following the conference. In addition, it will
also be available for 30 days on the Investor Relations section of the
Curis website at www.curis.com.

   Mr. Passeri is also participating on a conference panel entitled
"Bullseye: Novel Targets in Oncology" at 5:00 p.m. local time on the
same day.

   About Curis, Inc.

   Curis is a drug development company that is committed to
leveraging its innovative signaling pathway drug technologies to seek
to create new targeted small molecule drug candidates for cancer. In
expanding its drug development efforts in the field of cancer through
its targeted cancer drug development platform, Curis is building upon
its previous experiences in targeting signaling pathways for the
development of next generation targeted cancer therapies. For more
information, visit Curis' website at www.curis.com.

Curis, Inc.
Michael P. Gray, 617-503-6632
CFO & COO
mgray@curis.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.